|
Lindsay A. Rosenwald, M.D. has been a director of Cougar since May 2003. Dr. Rosenwald has served as chairman and chief executive officer of Paramount BioCapital, Inc. since 1991, as managing member of Paramount BioSciences LLC (and its predecessor, Paramount BioCapital, LLC) since 1996, and as chairman and chief executive officer of Paramount BioCapital Asset Management, Inc. since 1994. Paramount BioCapital, Inc. is a private investment banking firm and an SEC- and NASD- registered broker-dealer specializing in private placements of equity and debt securities for publicly traded and privately held companies in the biomedical, biopharmaceutical and medical technology industries. Paramount BioSciences, LLC is engaged in the research, formation and acquisition of seed-stage and distressed life science technologies and companies, identifying and evaluating a broad spectrum of therapeutic and medical technologies in order to capture innovations with significant commercial potential. Paramount BioCapital Asset Management, Inc. manages hedge and private equity funds focused on healthcare and life science companies. Dr. Rosenwald is chairman of the board of directors of Paramount Acquisition Corp., a publicly traded company (OTCBB:PMQC.OB). Dr. Rosenwald received a B.S. from Pennsylvania State University and an M.D. from the Temple University School of Medicine. | 